Investors & Media

Dedicated to delivering long-term investment value.

Hero Investors2

Featured News: CSL and uniQure Win 2023 Prix Galien USA Award

At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.

Stock Information

Updated stock ticker information for uniQure

  • Price:
  • Change:
  • Volume:

(Updated every 15 minutes)

Learn More

SEC Filings

Security and exchange commission filings for uniQure, including quarterly and annual reports

Learn More


Links to key uniQure corporate governance documents

Learn More

Upcoming Webcasts

No webcasts scheduled. Check back soon.

Webcast Archive

  • uniQure Huntington's Disease Update - AMT-130
    8:30 a.m. ET

    View Webcast
  • 2024 RBC Capital Markets Global Healthcare Conference
    2:35 p.m. ET - 3:00 p.m. ET

    View Webcast
  • Leerink Partners Global Biopharma Conference
    3:40 p.m. ET - 4:10 p.m. ET

    View Webcast
See All

Investor Presentations

  • July 2024 Huntington's Disease Program Update AMT-130 – Webcast Presentation

    View Presentation
  • Corporate Presentation – May 2024

    View Presentation
  • Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements

    View Presentation
  • Gene Therapy Information

    View Presentation
See All
uniQure Logo Twitter Icon LinkedIn Icon YouTube Icon Twitter Icon Arrow Slideshow Next Button